(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 105.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Eyepoint's revenue in 2026 is $31,371,000.On average, 14 Wall Street analysts forecast EYPT's revenue for 2026 to be $386,373,360, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $2,855,875,649. On average, 13 Wall Street analysts forecast EYPT's revenue for 2027 to be $3,721,064,970, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $11,526,123,893.
In 2028, EYPT is forecast to generate $26,617,295,009 in revenue, with the lowest revenue forecast at $5,723,431,770 and the highest revenue forecast at $85,768,044,600.